Cartesian Therapeutics Inc (NAS:RNAC)
$ 17.91 -0.74 (-3.97%) Market Cap: 455.18 Mil Enterprise Value: 250.63 Mil PE Ratio: 0 PB Ratio: 577.74 GF Score: 56/100

Q2 2022 Selecta Biosciences Inc Earnings Call Transcript

Aug 04, 2022 / 12:30PM GMT
Release Date Price: $56.4 (+13.94%)
Operator

Good day, and welcome to the Selecta Bio Second Quarter 2022 Earnings Release Conference Call. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to Kevin Tan, Chief Financial Officer of Selecta Bio. Please go ahead.

Kevin Tan
Selecta Biosciences, Inc. - CFO

Thank you, and good morning. Welcome to our second quarter 2022 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website, worldwide web selectabio.com, and our quarterly report on Form 10-Q for the quarter ended June 30, 2022, which we intend to file in the coming days with the Securities and Exchange Commission, or SEC.

Joining me today are Carsten Brunn, President and Chief Executive Officer; Peter Traber, Chief Medical Officer; and Kei Kishimoto, Chief Scientific Officer.

During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot